#zepbound

Medicare will cover Wegovy and Zepbound for weight loss starting July 1, 2026, at a flat $50/month copay. Here is everything you need to know about eligibility, the prior authorization process, how to prepare, and what happens when the BALANCE Model launches in January 2027.

The two most prescribed GLP-1 weight loss drugs go head to head — clinical results, pricing, side effects, insurance, and which one is right for you.

Retatrutide achieved 28.7% weight loss in Phase 3 trials — nearly double semaglutide. Here's everything known about Eli Lilly's next-generation triple-agonist, from clinical data to expected approval timeline.

Medicare will begin covering GLP-1 weight loss medications at $50/month starting July 2026. Here's who qualifies, how it works, and what comes next.

From $25/month with a savings card to $1,350 list price — the GLP-1 pricing landscape is confusing. Here's every option with real numbers.

Everything you need to know about GLP-1 receptor agonists — how they work, what the clinical trials show, side effects, eligibility, and how to choose a provider.